As of November 6, 2026, Ultragenyx Pharmaceutical Inc is a publicly traded company (Nasdaq: RARE); its largest reported holder is Vanguard, with 8.6% on Schedule 13G/A of October 30, 2026, then BlackRock (8.3%). The largest insider holding is Emil D. Kakkis, the chief executive and president, with 2,694,724 shares (2.6% of shares outstanding), per Form 4 of April 20, 2026 (Schedule 13G/A, October 30, 2026).
Is this your company?
About to sign with, pay or invest in Ultragenyx Pharmaceutical Inc? See the free Snapshot first.
Free to see. No signup.
Is Ultragenyx Pharmaceutical Inc a real, registered company?
- Ultragenyx Pharmaceutical Inc files with the SEC under CIK 1515673 (its SEC filings).
- Its shares are listed under the ticker RARE on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Novato, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Ultragenyx Pharmaceutical Inc in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 2 exit or restructuring plans reported on Form 8-K, Item 2.05 (latest filed 2026-11-03).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vanguard (filed 2026-10-30).
Who are Ultragenyx Pharmaceutical Inc's owners and officers?
Ultragenyx Pharmaceutical Inc: incorporated in Delaware; business address in Novato, California; industry Pharmaceutical Preparations (Form 8-K, 2026-11-03).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-30 | Vanguard Portfolio Management | 8.6% |
| Schedule 13G, 2026-10-20 | Madison Avenue International LP | 6.4% |
| Schedule 13G, 2026-08-14 | Rtw Investments, LP | 7.9% |
| Schedule 13G, 2026-08-13 | Aqr Capital Management, LLC | 6.66% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 6.3% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.13% |
| Schedule 13G/A, 2026-07-31 | Vanguard Portfolio Management | 6.95% |
| Schedule 13G/A, 2026-07-30 | Blackrock, Inc. | 8.3% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 5.1% |
| Schedule 13G, 2026-04-29 | Vanguard Portfolio Management | 5.5% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-05 | Fmr LLC | 3.5% |
Questions about who owns Ultragenyx Pharmaceutical Inc
Who owns Ultragenyx Pharmaceutical Inc?
On this page, 7 holders' latest ownership filings report 5% or more of Ultragenyx Pharmaceutical Inc: Vanguard Portfolio Management (8.6%, Schedule 13G/A, filed 2026-10-30), Blackrock, Inc. (8.3%, Schedule 13G/A, filed 2026-07-30), Rtw Investments, LP (7.9%, Schedule 13G, filed 2026-08-14), Aqr Capital Management, LLC (6.66%, Schedule 13G, filed 2026-08-13) and Madison Avenue International LP (6.4%, Schedule 13G, filed 2026-10-20); 2 more are listed above.
Who are the largest shareholders of Ultragenyx Pharmaceutical Inc?
By the share each holder's latest filing reports, the largest holders of Ultragenyx Pharmaceutical Inc on this page are Vanguard Portfolio Management (8.6%), Blackrock, Inc. (8.3%) and Rtw Investments, LP (7.9%).
When did Vanguard Portfolio Management buy into Ultragenyx Pharmaceutical Inc?
The filings give report dates, not purchase dates. The earliest filing from Vanguard Portfolio Management on this page is the Schedule 13G, filed 2026-04-29, reporting 5.5%; its latest, Schedule 13G/A filed 2026-10-30, reports 8.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Ultragenyx Pharmaceutical Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ultragenyx Pharmaceutical Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ultragenyx Pharmaceutical Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Ultragenyx Pharmaceutical Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 2,694,724 shares (2.6% of shares outstanding), 735,739 held directly and 1,958,985 indirectly (Form 4, 2026-04-20).
- , the cbo and executive vice president: 264,730 shares (0.26% of shares outstanding) (Form 4, 2025-03-04).
- Huang Dennis Karl: 147,845 shares (0.15% of shares outstanding) (Form 4, 2026-04-20).
- Pinion John Richard: 133,142 shares (0.13% of shares outstanding) (Form 4, 2026-04-20).
- , the executive vice president and chief commercial officer: 118,410 shares (0.12% of shares outstanding) (Form 4, 2026-04-20).
Shares outstanding: 101,924,068 as of 2026-10-29, from the company's latest SEC cover page.
How much has Ultragenyx Pharmaceutical Inc raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-11-03).
Red flags found
2 exit or restructuring plans on Form 8-K (latest Form 8-K, 2026-11-03).
Keep reading
More on Ultragenyx Pharmaceutical Inc and the records around it.
Ultragenyx Pharmaceutical Inc elsewhere on the record
- Layoff notices Nov 2026
- 5%+ stake filings Oct 2026
Companies that share a holder
- Madison Avenue International LP also filed stake reports on 11 other companies: Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026), Theravance Biopharma, Inc. (Aug 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/ultragenyx-pharmaceutical